Vinorelbine and cisplatin in metastatic breast cancers
Özet
Nineteen patients with metastatic breast cancer who had been previously treated with a regimen containing doxorubicin and docetaxel were included in our study. Cisplatin (75 mg/m2 day 1) and vinorelbine (25 mg/m 2 days 1 and 8) were administered every 3 weeks. The median age was 51 yr (41-69). A total of 98 cycles of chemotherapy was given, with a median of 6 cycles (3-6). Four patients achieved a complete response (21%), and six patients achieved a partial response (32%), with an overall response rate of 53%. Stable disease was observed in five patients (26%), four patients had progressive disease (21%). The median time to progression was 4 months (0-13) and median overall survival was 46 months (39-52). Grade 3-4 toxicities were febrile neutropenia 1%, anemia 3%, neutropenia 11%, nausea-vomiting 1%. This cisplatin/vinorelbine regimen is well tolerated and active in patients who failed anthracyclines and docetaxel treatment.
